|Systematic (IUPAC) name|
|Trade names||Ansaid, Ocufen, Strepfen|
|Protein binding||> 99%|
|Biological half-life||4.7-5.7 hours|
|ATC code||M01AE09 (WHO) , M02, R02, S01|
|PDB ligand ID||FLP (, )|
|Molecular mass||244.261 g/mol|
|Melting point||117 °C (243 °F)|
Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily indicated as a pre-operative anti-miotic (in an ophthalmic solution) as well as orally for arthritis or dental pain. It is generic and is marketed under brand names worldwide, including "Ansaid" and "Froben".
It was derived from propionic acid by the research arm of Boots UK during the 1960s, a period which also included the discovery of ibuprofen, indometacin, diclofenac, naproxen, ketoprofen, and sulindac.:34
Side effects are analogous to those of ibuprofen
- "Lexicomp: Flurbiprofen". Lexicomp. Wolters Kluwer. Retrieved 25 September 2015.
- Drugs.com Flurbiprofen listings at drugs.com Page accessed July 3, 2015
- Halford, GM; Lordkipanidzé, M; Watson, SP (2012). "50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams.". Platelets. 23 (6): 415–22. PMID 22098129. doi:10.3109/09537104.2011.632032.
- Rainsford KD. Fifty years since the discovery of ibuprofen. Inflammopharmacology. 2011 Dec;19(6):293-7. PMID 22120888
- Janos Fischer and C. Robin Ganellin. Analogue-based Drug Discovery II. John Wiley & Sons, 2010 ISBN 9783527632121
|This drug article relating to the respiratory system is a stub. You can help Infogalactic by expanding it.|
|This drug article relating to the musculoskeletal system is a stub. You can help Infogalactic by expanding it.|
|This analgesic-related article is a stub. You can help Infogalactic by expanding it.|